Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial

NCT02049307 ↗

Phase 2 Completed 108 enrolled Hennepin Healthcare Research Institute

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the potential effectiveness of losartan (100mg daily) for reducing inflammation and improving immune recovery.

Timeline

Start: 2014-10-16
Primary completion: 2018-12-14
Completion: 2018-12-14

Publications

Baker JV, Wolfson J, Collins G, Morse C, Rhame F, Liappis AP, Rizza S, Temesgen Z, Mystakelis H, Deeks S, Neaton J, Schacker T, Sereti I, Tracy RP. Losartan to reduce inflammation and fibrosis endpoints in HIV disease. AIDS. 2021 Mar 15;35(4):575-583. doi: 10.1097/QAD.0000000000002773.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Losartan	Other / unclassified	100 mg	—

Indications

No indication recorded.